Detalles de la búsqueda
1.
Cure indicators and prevalence by stage at diagnosis for breast and colorectal cancer patients: A population-based study in Italy.
Int J Cancer
; 155(2): 270-281, 2024 Jul 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38520231
2.
Indicators of cure for women living after uterine and ovarian cancers: a population-based study.
Am J Epidemiol
; 2024 Apr 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38629583
3.
The emerging predictive and prognostic role of HER2 in HER2-negative early breast cancer: a retrospective study.
Breast Cancer Res Treat
; 2024 May 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-38743174
4.
Patient presentation, skin biopsy utilization and cutaneous malignant melanoma incidence and mortality in northern Italy: Trends and correlations.
J Eur Acad Dermatol Venereol
; 37(2): 293-302, 2023 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-36181283
5.
The relative contribution of the decreasing trend in tumour thickness to the 2010s increase in net survival from cutaneous malignant melanoma in Italy: a population-based investigation.
Br J Dermatol
; 187(1): 52-63, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35253204
6.
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.
Lancet Oncol
; 21(11): 1455-1464, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-33152285
7.
Salivary MicroRNA for Diagnosis of Cancer and Systemic Diseases: A Systematic Review.
Int J Mol Sci
; 21(3)2020 Jan 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-32019170
8.
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial.
BMC Med
; 17(1): 207, 2019 11 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-31747948
9.
Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2- breast cancer that had progressed during or after prior endocrine therapy.
Breast Cancer Res
; 19(1): 18, 2017 02 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-28183331
10.
A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer.
Breast Cancer Res Treat
; 165(3): 601-609, 2017 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-28681171
11.
Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer.
Oncologist
; 20(9): 1001-10, 2015 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-26245675
12.
Hormone Receptor-Positive/HER2-Positive Breast Cancer: Hormone Therapy and Anti-HER2 Treatment: An Update on Treatment Strategies.
J Clin Med
; 13(7)2024 Mar 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-38610638
13.
Genetic Basis of Breast and Ovarian Cancer: Approaches and Lessons Learnt from Three Decades of Inherited Predisposition Testing.
Genes (Basel)
; 15(2)2024 Feb 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-38397209
14.
RAD51 as a biomarker for homologous recombination deficiency in high-grade serous ovarian carcinoma: robustness and interobserver variability of the RAD51 test.
J Pathol Clin Res
; 9(6): 442-448, 2023 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37504067
15.
Nine-Week Versus One-Year Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 10-Year Update of the ShortHER Phase III Randomized Trial.
J Clin Oncol
; 41(32): 4976-4981, 2023 Nov 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37748109
16.
Randomized, open-label, phase II, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with locally advanced, inflammatory, or early HER2-positive breast cancer-Immun-HER trial (GOIRC-01-2016).
J Immunother Cancer
; 11(11)2023 11 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-38016718
17.
Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial.
J Clin Oncol
; 41(2): 198-205, 2023 01 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-36332179
18.
The descriptive epidemiology of melanoma in Italy has changed - for the better.
Ital J Dermatol Venerol
; 158(6): 483-492, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-38015485
19.
BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors.
Cancer Res
; 83(10): 1699-1710, 2023 05 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-37129948
20.
Role of Fcγ receptors in HER2-targeted breast cancer therapy.
J Immunother Cancer
; 10(1)2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34992090